Search
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalVorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Products: ZOLINZA®VORINOSTAT 100 MG CAPSULASNicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnIt is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload [A20325]. … It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.
Products: Dancor 10 mg - Tabletten, IKOREL 10 MG TABLET, 60 ADETAmbrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalIn addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. … It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: AMANTİN 10 MG FİLM KAPLI TABLET, 10 TABLET, ANCATİS 10 MG FİLM KAPLI TABLET, 10 TABLETCanrenoic acid
go.drugbank.com/drugs/DB09015ApprovedInvestigationalWithdrawnLike spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
Products: Aldactone 200 mg/ 10 ml Injektionslösung, POTASSIO CANRENOATO EGLovastatin
go.drugbank.com/drugs/DB00227ApprovedInvestigational[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, [rosuvastatin] is considered the most potent; doses of 10 to 40mg [rosuvastatin] per day … [A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: MEVACOR 10 MG, LOSTIN® 20 MGFerric hydroxide
go.drugbank.com/drugs/DB13423InvestigationalProducts: FERIFER 100 MG/5 ML ORAL COZELTI ICEREN 10 KASIK, FERIFER 100 MG/5 ML ORAL COZELTI ICEREN 30 KASIKCarboxymethylcellulose
go.drugbank.com/drugs/DB11059ApprovedInvestigationalCarboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. … It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining [A33029
Mixtures: GenTeal Moderate to SevereProducts: MEDCLOT Hemostatic Dressing 10 cm x 10 cm, MEDCLOT Hemostatic Dressing 7.5 cm x 150 cmTrifluoperazine
go.drugbank.com/drugs/DB00831ApprovedA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Mixtures: Stelabid No 2, Stelabid No 1Categories: Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor AntagonistsVismodegib
go.drugbank.com/drugs/DB08828ApprovedInvestigationalVismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO). … In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsProducts: Erigib 150 mg Sert Kapsül, 28 ADET, ERIVEDGE 150 MG SERT KAPSÜL ,28 KAPSÜLButamirate
go.drugbank.com/drugs/DB13731InvestigationalProducts: SINECOD 50 MG DEPO TABLET, 10 ADET, CODACTIV 7,5 MG/5 ML SURUP, 100 ML